1 – 10 of 13
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2020
-
Mark
Genetic signature of prostate cancer mouse models resistant to optimized hK2 targeted α-particle therapy
2020) In Proceedings of the National Academy of Sciences of the United States of America 117(26). p.15172-15181(
- Contribution to journal › Article
- 2016
-
Mark
Radioimmunotherapy of prostate cancer targeting human kallikrein-related peptidase 2
(
- Contribution to journal › Article
-
Mark
Porous silicon microarray for simultaneous fluorometric immunoassay of the biomarkers prostate-specific antigen and human glandular kallikrein 2
(
- Contribution to journal › Article
- 2014
-
Mark
Radioimmunoimaging and Radioimmunotherapy of Prostate Cancer Preclinical evaluation of kallikrein related peptidase 2 targeting
2014)(
- Thesis › Doctoral thesis (monograph)
- 2008
-
Mark
The Kallikrein-Related Peptidases hK2 and PSA with Emphasis on Genetic Variation, Secretion, and Sperm Motility
(
- Thesis › Doctoral thesis (compilation)
- 2007
-
Mark
Assessments of PSA Forms and hK2 as Very Early Predictors of Prostate Cancer
2007)(
- Thesis › Doctoral thesis (compilation)
- 2006
-
Mark
Risk assessment for biochemical recurrence prior to radical prostatectomy: significant enhancement contributed by human glandular kallikrein 2 (hk2) and free prostate specific antigen (PSA) in men with moderate PSA-elevation in serum
(
- Contribution to journal › Article
-
Mark
Impact of renal dysfunction on serum Prostate-Specific Antigen
2006)(
- Thesis › Doctoral thesis (compilation)
- 2003
-
Mark
The role of human glandular kallikrein 2 for prediction of pathologically organ confined prostate cancer
(
- Contribution to journal › Article
- 2000
-
Mark
Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum
(
- Contribution to journal › Article